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Abstract
Objective: Our aim was to examine the relative contributions of changes in dietary fat intake and use of cholesterol-
lowering medications to changes in concentrations of total cholesterol among adults in the United States from 1988–1994
to 2007–2008.
Method: We used data from adults aged 20–74 years who participated in National Health and Nutrition Examination
Surveys from 1988–1994 to 2007–2008. The effect of change in dietary fat intake on concentrations of total cholesterol was
estimated by the use of equations developed by Keys, Hegsted, and successors.
Results: Age-adjusted mean concentrations of total cholesterol were 5.60 mmol/L (216 mg/dl) during 1988–1994 falling to
5.09 mmol/L (197 mg/dl) in 2007–2008 (P,0.001). No significant changes in the intake of total fat, saturated fat,
polyunsaturated fat, and dietary cholesterol were observed from 1988–1994 to 2007–2008. However, the age-adjusted use
of cholesterol-lowering medications increased from 1.6% to 12.5% (P,0.001). The various equations suggested that
changes in dietary fat made minimal contributions to the observed trend in mean concentrations of total cholesterol. The
increased use of cholesterol-lowering medications was estimated to account for approximately 46% of the change.
Discussion: Mean concentrations of total cholesterol among adults in the United States have declined by ,4% since 1988–
1994. The increased use of cholesterol-lowering medications has apparently accounted for about half of this small fall.
Further substantial decreases in cholesterol might be potentially achievable by implementing effective and feasible public
health interventions to promote the consumption of a more healthful diet by US adults.
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Introduction
The intake of dietary fats is an important lifestyle factor that
affects concentrations of total cholesterol. Work by Keys and by
Hegsted and their colleagues resulted in the development of
equations that related changes in the intake of saturated fatty
acids, polyunsaturated fatty acids, and dietary cholesterol to
changes in concentrations of total cholesterol [1,2]. The discovery
and subsequent development of statins (HMG-CoA reductase
inhibitors or 3-hydroxy-3-methylglutaryl CoA reductase inhibi-
tors) provided clinicians with a powerful new class of medications
to improve cholesterol concentrations in their patients.
Understanding to what extent dietary change and use of
cholesterol-lowering medications affected the trend in the
concentrations of total cholesterol in the U.S. population is
important firstly to yield insights into the dynamics of the trend in
the mean concentration of total cholesterol and secondly to inform
future public health and clinical approaches necessary to achieve
the Healthy People 2020 objective that calls for reducing the mean
concentration of total cholesterol to 4.60 mmol/L (177.9 mg/dl)
[3]. The principal objective of this study was to estimate the
impact of changes in dietary fat intake and use of cholesterol-
lowering medications on concentrations of total cholesterol
subsequent to 1987 when the first statin was introduced in the
United States. In addition, secondary objectives included 1)
examining trends in dietary fat intake among U.S. adults and 2)
examining trends in the use of cholesterol-lowering medications
among U.S. adults. Although the time frame for the study covers
the period from 1988–1994 to 2007–2008, we also present data
concerning trends in dietary fat intake among U.S. adults starting
with the period 1971–1975 to give a historical perspective.
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Materials and Methods
Ethics statement
Because our study used existing public-use data sets that are
readily available, our study was exempt from human subjects
review.
Data sources
We used data from eight NHANES cycles: 1971–1975, 1976–
1980, 1988–1994, 1999–2000, 2001–2002, 2003–2004, 2005–
2006, and 2007–2008. In brief, each survey employed a complex
multistage cluster design to select samples of the civilian,
noninstitutionalized population in the United States. Selected
participants were interviewed in their homes and invited for an
examination that included completing additional questionnaires,
receiving various examinations, and providing biological speci-
mens including blood and urine. Detailed descriptions of each of
these surveys may be found elsewhere [4–9].
Variables
The methods used to measure serum total cholesterol and low-
density lipoprotein cholesterol have been summarized elsewhere
[10,11].
Dietary data were obtained by using a single 24-hour recall
from 1971–1975 through 2001–2002 and two 24-hour recalls
starting with the 2003–2004 survey [12,13]. To maintain
consistency across surveys, we used only data from the first 24-
hour recall for surveys that collected more than one. Data files of
all surveys contained information for the intake of total fat,
saturated fat, dietary cholesterol, and total energy. Starting with
NHANES III (1988–1994), data files also contained information
for the intake of polyunsaturated fat and monounsaturated fat.
We used the following formula by Keys and colleagues to
estimate the effect of changes in the intake of saturated fat,
polyunsaturated fat, and dietary cholesterol on serum concentra-
tions of total cholesterol (mg/dl): 1.35 * (2DS – DP)+1.5 * DC0.5,
where S=% of energy from saturated fatty acids, P =% of energy
from polyunsaturated fatty acids, and C=dietary cholesterol [mg/
1000 kcal] [1]. We also used a formula developed by Howell and
colleagues to estimate the effect of changes in the three dietary
sources of fat on concentrations of total cholesterol (mg/dl): 1.918
* DS20.900 * DP+0.0222 * DC [14]. S and P are both expressed
as percent of total energy, whereas C is expressed in mg/day. In
addition, we estimated the change in fasting concentrations of low-
density lipoprotein cholesterol (mmol/L) from the equation: 0.036
DS – 0.022 DP – 0.008 DM+0.0005 * DC, where S=% of energy
from saturated fatty acids, P=% of energy from polyunsaturated
fatty acids, M=% of energy from monounsaturated fatty acids,
and C=dietary cholesterol [mg/day] [15].
Participants could report up to 16 prescription medications in
NHANES III and up to 20 prescription medications in NHANES
2007–2008 and, if available, were asked to show them to the
interviewers. Participants who had been prescribed one of the
following medications were considered to be using cholesterol-
lowering medications: atorvastatin, cerivastatin, fluvastatin, lova-
statin, lovastatin & niacin, pravastatin, simvastatin, ezetimibe &
simvastatin, rosuvastatin, cholestyramine, colestipol, colesevelam,
and ezetimibe.
To estimate the possible effect of the use of these medications on
the decrease in mean concentrations of total cholesterol and low-
density lipoprotein cholesterol, we used the following formula: D
prevalence of cholesterol-lowering medications use from 1988–
1994 to 2007–2008 * estimated reduction in total cholesterol
caused by these medications * suboptimal dosing * compliance/
change in mean concentrations of lipid.
We estimated the proportion of suboptimal dosing at 75%
[16,17]. Several studies peg compliance with the use of statins at
50% to 55% [18–20], and we used a value of 55%.
We also estimated predicted mean concentrations of total
cholesterol in the absence of use of cholesterol-lowering medica-
tions for 1988–1994 and 2007–2008. For these calculations, we
assumed that cholesterol-lowering medications lower concentra-
tion of total cholesterol by 2.0 mmol/L (77 mg/dl).
Data analysis
We limited our analysis to adults aged 20–74 years. We chose
74 years as our upper age limit as that age represented the upper
age limit in early surveys such as NHANES I. The distribution of
the projected 2000 US population was used to perform age-
adjustment using the direct method [21]. Using time in years as
determined from the approximate midpoints of the surveys, tests
for trend adjusted for age as a continuous covariate were
calculated using linear regression for continuous variables and
log-linear regression for dichotomous variables. Analyses that
incorporated sampling weights and design variables were con-
ducted using SUDAAN to account for the complex sampling
designs of the surveys. Sample sizes are shown as unweighted
numbers.
Results
The numbers of adults aged 20–74 years who attended the
NHANES examinations were 16165 in 1971–1975, 15364 in
1976–1980, 16115 in 1988–1994, 4201 in 1999–2000, 4616 in
2001–2002, 4251 in 2003–2004, 4381 in 2005–2006, and 5168 in
NHANES 2007–2008. Sample sizes for the various analyses were
generally less due to missing values for the study variables. These
sample sizes pertain to the descriptive epidemiologic analyses and
not to the modeling part of the study that employed group means
from two time periods.
The mean age was 42.8 years in NHANES I and 44.0 years in
NHANES 2007–2008 (P for linear trend ,0.001). The percentage
of participants who were men was about 47% in NHANES I and
48% in NHANES 2007–2008 (P for linear trend= 0.140). The
percentage of non-Hispanic white participants decreased from
89% to 69% (P for linear trend ,0.001). The percentage of
participants who had graduated with at least a high school
education increased from 64% to 81% (P for linear trend ,0.001).
Total cholesterol and low-density lipoprotein cholesterol
The age-adjusted mean concentration of total cholesterol
decreased from 5.60 mmol/L (216 mg/dl) during 1971–1975 to
5.09 mmol/L (197 mg/dl) during NHANES 2007–2008
(P,0.001) (Figure 1). The change was particularly pronounced
among users of cholesterol-lowering medications among whom
mean concentrations of total cholesterol decreased from
5.80 mmol/L (224 mg/dl) to 4.99 mmol/L (193 mg/dl)
(P,0.001) whereas concentrations decreased from 5.29 mmol/L
(204 mg/dl) to 5.19 mmol/L (201 mg/dl) (P = 0.022) among
adults who did not use cholesterol-lowering medications
(Figure 2). The age-adjusted mean concentrations of low-density
lipoprotein cholesterol were 3.55 mmol/L (137 mg/dl) during
1976–1980 and 3.00 (116 mg/dl) during NHANES 2007–2008
(P,0.001). For both total cholesterol and low-density lipoprotein
cholesterol, tests of interaction indicated that declines in concen-
tration of these lipids were stronger among participants who used
Determinants of Trends in Cholesterol
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cholesterol-lowering medications than among those who did not (p
interaction ,0.001 for both lipids).
Dietary fat intake from 1971–1975 to 2007–2008
The absolute age-adjusted mean intake of total fat increased
significantly (P=0.003) (Table 1). The largest mean was recorded
for the 2003–2004 period. When expressed as a percentage of
energy intake, total fat intake decreased significantly largely driven
by the decrease from 1976–1980 to 1999–2000 (P,0.001). The
different impressions regarding the direction of change for mean
intake of total fat intake and total fat intake expressed as a
percentage of energy intake reflects the increase in energy intake
during this period. The mean intake of saturated fat, both in
absolute terms (P=0.002) and expressed as a percentage of energy
intake (P,0.001), decreased significantly reflecting the large
decline from 1971–1975 to 2001–2002. Dietary cholesterol
decreased significantly, both in absolute terms and expressed per
1,000 kcals, largely reflecting a drop of about 27% from 1971–
1975 to 1988–1994. Dietary cholesterol intakes then rose slightly
between 1988–1994 and 2007–2008. When we used the data for
two 24-hour recalls for the 2-year cycles of 2003–2004, 2005–
2006, and 2007–2008, the results changed minimally.
Cholesterol-lowering medications from 1988–1994 to
2007–2008
The use of any cholesterol-lowering medications increased
progressively from 1.6% during 1988–1994 to 12.5% 2007–2008
(P,0.001) (Figure 3). The vast majority of this change was
attributable to the strong increase in the use of statins.
Effect of changes in dietary fat intake on concentrations
of total cholesterol and low-density lipoprotein
cholesterol from 1988–1994 to 2007–2008
The changes in the intake of saturated fat and polyunsaturated
fat had a negligible effect on concentrations of total cholesterol
Figure 1. Age-Adjusted Mean Concentrations of Total Cholesterol (TC) and Low-Density Lipoprotein Cholesterol (LDLC) among U.S.
Adults Aged 20–74 Years. Data points were plotted at the approximate midpoint of the study period.
doi:10.1371/journal.pone.0065228.g001
Figure 2. Age-Adjusted Mean Concentrations of Total Cholesterol among U.S. Adults Aged 20–74 Years, by use of cholesterol-
lowering medications (CLM). Data points were plotted at the approximate midpoint of the study period.
doi:10.1371/journal.pone.0065228.g002
Determinants of Trends in Cholesterol
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(Figure 4). The Keys equation suggested that the increase in the
intake of dietary cholesterol after 1988–1994 should have
increased mean concentrations of total cholesterol by about
0.10 mmol/L (3.9 mg/dl). Thus, the net effect of the changes in
fat intake should have increased mean concentrations of total
cholesterol by about 0.09 mmol/L (3.3 mg/dl). Yet, the mean
age-adjusted concentration of total cholesterol actually decreased
by about 0.19 mmol/L (7.5 mg/dl). Estimating mean intakes of
dietary fats with two 24-hour dietary recalls for the periods 2003–
2004, 2005–2006, and 2007–2008 had very little effect on
analyses.
A subsequent analysis by Hegsted suggested that earlier studies
had overestimated the relationship between changes in the intake
of dietary cholesterol and changes in circulating concentrations of
total cholesterol [22]. Using a revised equation he and colleagues
proposed [23], concentrations of total cholesterol were predicted
to have increased by approximately 0.02 mmol/L (0.5 mg/dl)
(Figure 4). Using this value, the net predicted change in total
cholesterol attributable to changes in the three dietary sources of
fats was 20.0006 mmol/L (0.02 mg/dl).
When we applied the formula developed by Howell and
colleagues to our data [14], changes in the intake of saturated fat
and polyunsaturated fat would have decreased concentrations of
total cholesterol by 0.01 mmol/L (0.4 mg/dl) and 0.002 mmol/L
(0.1 mg/dl), respectively. Changes in the intake of dietary
cholesterol would have increased concentrations of total choles-
terol by 0.01 mmol/L (0.2 mg/dl) (Figure 4). Thus, the net effect
of these changes would have decreased concentrations of total
cholesterol by 0.01 mmol/L (0.2 mg/dl).
The changes in the intake of dietary fatty acids and cholesterol
also produced essentially no change in the concentration of low-
density lipoprotein cholesterol (data not shown).
Effect of changes in the use of cholesterol-lowering
medications on mean concentrations of total cholesterol
and low-density lipoprotein cholesterol
The increased use of cholesterol-lowering medications resulted
in decreases of 0.09 mmol/L (3.5 mg/dl) of total cholesterol and
0.09 mmol/L (3.5 mg/dl) of low-density lipoprotein cholesterol,
thus representing approximately 46% of the decrease in mean
concentrations of total cholesterol and 29% of the decrease in low-
density lipoprotein cholesterol. The results of sensitivity analyses
whereby the levels of suboptimal dosing and the levels of
compliance were allowed to vary from 25% to 90% are shown
in Figure 5. Alternatively, we estimated that in the absence of the
use of cholesterol-lowering medications, mean concentrations of
total cholesterol would have been 5.31 mmol/L (205 mg/dl)
during 1988–1994 and 5.27 mmol/L (204 mg/dl) during 2007–
2008 (Figure 6). These recalculated means assumed that
cholesterol-lowering medications would have lowered concentra-
tions of total cholesterol by about 2.0 mmol/L (77 mg/dl) and
that compliance was 55%.
Discussion
Our analyses suggest that the modest recent declines in the
mean concentration of total cholesterol since 1988–1994 mainly
reflect the increased use of cholesterol-lowering medications. In
contrast, changes in the intake of various dietary fats had little
effect on concentrations of total cholesterol. Because we used data
from NHANES that are representative of the noninstitutionalized
civilian population, our results are largely reflective of the U.S.
population aged 20–74 years.
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The role of cholesterol-lowering medications in explaining
almost half of the small decrease in mean concentration of total
cholesterol among U.S. adults during the past two decades
contrasts markedly with findings from Finland and Sweden
[24,25]. Prior to the introduction of statins, mean concentrations
of total cholesterol in Finland and Sweden were higher than those
in the United States [26,27]. Furthermore, mean intake of
saturated fat was considerably higher in Finland and likely in
Sweden than in the United States [25,28]. During this period,
dietary modification was the principal option to bring about
population-wide reductions in mean concentrations of total
cholesterol. As a result of the North Karelia project, a paradigm
to change dietary intake on a population-wide basis in Finland was
developed [29]. Thus a focus on modifying the intake of dietary
fats in Finland and Sweden produced a pronounced impact of
dietary efforts on trends in lipid concentrations. In contrast, higher
use of cholesterol-lowering medications in the United States than
Finland and Sweden at approximate similar points in time helps to
explain the differences between the countries in the relative
importance of the two major contributing factors in lowering
mean concentrations of total cholesterol [24,25].
As acknowledged by the 2010 US Dietary Guidelines [30] and
as shown by our analyses, the intakes of total fat, saturated fat,
polyunsaturated fat have changed little in the past two decades,
and thus appear to have contributed little to lowering population
mean concentrations of total cholesterol and low-density lipopro-
tein cholesterol in the United States. Furthermore, the intake of
dietary cholesterol has inched upwards since 1988–1994.
In contrast, the use of cholesterol-lowering medications, mainly
statins, has progressively increased during the past two decades
Figure 3. Age-Adjusted Percent Use (95% Confidence Interval) of Cholesterol-Lowering Medications (CLM) and Statins among U.S.
Adults Aged 20–74 Years.
doi:10.1371/journal.pone.0065228.g003
Figure 4. Predicted Changes in Concentration of Total Cholesterol Attributable to Changes in the Dietary Intake of Saturated Fat
(SFA), Polyunsaturated Fat (PUFA), and Dietary Cholesterol and Actual Change in Concentration of Total Cholesterol (Grey Bar)
among U.S. Adults Aged 20–74 Years from 1988–1994 to 2007–2008.
doi:10.1371/journal.pone.0065228.g004
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and currently appears to be rising by about one percentage point
per year among U.S. adults. Given the more or less stationary
patterns in the consumption of dietary fats, future progress in
lowering mean concentrations of total cholesterol in the United
States will likely be heavily dependent on the increased use of these
medications. In contrast, dietary interventions to decrease
concentrations of total cholesterol are potentially powerful but
currently relatively neglected in the United States. Furthermore,
increased pressures to eliminate industrial trans fats and decrease
the content of saturated fats in the food supply may reduce total
cholesterol concentrations in the U.S. population in future.
Several study limitations should be acknowledged. The study
used an ecologic design that is subject to various methodologic
issues [31]. Because we used data from national surveys that
included different sets of participants, we were unable to work with
data at the individual level and instead worked with grouped data.
Thus, the results of our study are potentially subject to an ecologic
bias.
Dietary data were collected with a single 24-hour recall in most
surveys, and when two such recalls were obtained, we used only
the first one to maintain consistency across surveys. Although a
larger number of recalls would have yielded better estimates of
intakes, mean intakes of such recalls are generally thought to
provide reasonable estimates of actual population means. Also,
food data bases used to calculate dietary intake have changed, and
the operational details of the 24-hour recall used in NHANES
have gradually evolved.
Our estimates explained almost half of the modest fall in
concentrations in total cholesterol and about one-fourth of the fall
in low-density lipoprotein cholesterol. This gap may be due to
imprecise estimates of suboptimal dosing and compliance with the
use of cholesterol-lowering medications, the contribution of dietary
Figure 5. Sensitivity Analysis Illustrating Potential Effects of Varying Assumptions Concerning the Levels of Suboptimal Dosing
and Compliance on the Percentage of the Decline in Concentrations of Total Cholesterol Explained by the Use of Cholesterol-
Lowering Medications among U.S. Adults Aged 20–74 years from 1988–1994 to 2007–2008.
doi:10.1371/journal.pone.0065228.g005
Figure 6. Age-Adjusted Actual and Predicted Mean Concentrations of Total Cholesterol among U.S. Adults Aged 20–74 Years.
doi:10.1371/journal.pone.0065228.g006
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components other than dietary fats, or other factors that affect
concentrations of total cholesterol.
Although data on the intake of trans-fatty acids were not
available, a recent analysis showed that concentrations of these fats
in white U.S. adults halved from 2000 to 2009 suggesting that the
intake of these fats decreased [32]. Thus, some of the unexplained
proportion of the decrease concentrations of total and low-density
lipoprotein cholesterol may reflect decreased consumption of
trans-fatty acids. Replacing 1% of transfats with a mix of mono
and poly-unsaturated fats should reduce total serum cholesterol by
about 0.04 mmol/L (1.5 mg/dl) [33].
After accounting for suboptimal dosing and compliance, we
estimated that the reduction in concentrations of total cholesterol
by cholesterol-lowering medications amounted to 0.825 mmol/L
(32 mg/dl). Unfortunately, good national data about these
parameters are unavailable, and we relied on less representative
data. Other authors have used different estimates and assumed
that the use of cholesterol-lowering medications decreased
concentrations of total cholesterol by 25% or by 1.5 mmol/L
(58 mg/dl) [24,25]. Had we used the more optimistic estimate of
1.5 mmol/L (58 mg/dl) instead of 0.825 mmol/L (32 mg/dl), the
increased use of cholesterol-lowering medications would have
accounted for 82% of the decrease in mean concentrations of total
cholesterol and 50% of the decrease in mean concentrations of
low-density lipoprotein cholesterol.
Because estimates of low-density lipoprotein cholesterol were
calculated using the Friedewald equation [34], measurements of
concentrations of high-density lipoprotein cholesterol and triglyc-
erides are critical. Mean concentrations of high-density lipoprotein
cholesterol increased among U.S. adults during the study period,
and changes in the methods used to measure high-density
lipoprotein cholesterol were proposed as one explanation for the
apparent increase [11]. If this explanation holds, the change in the
concentration of low-density lipoprotein cholesterol would have
been overestimated and the change attributed to increased use of
cholesterol-lowering medications underestimated.
In conclusion, our results suggest that the modest reductions in
mean concentrations of total cholesterol in the U.S. population
during the past two decades largely reflect the increased use of
cholesterol-lowering medications rather than a decreased dietary
intake of fats. The experience from other countries [24,25] and
from the United States [35,36] prior to the rapid escalation of the
use of cholesterol-lowering medications emphasizes that dietary
changes could still play a powerful role in driving down the mean
concentration of total cholesterol in the population. Our analyses
may contribute to the dialogue about the need for effective public
health policy to improve lipid concentrations through better diet in
the United States particularly in light of the new Million Heart
Initiative that seeks to prevent one million heart attacks over the
next five years in part through public health efforts to improve diet
[37]. Failing that, escalating expenditure on cholesterol-lowering
medications will likely continue to be the principal determinant of
trends in total cholesterol concentrations in the United States.
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